Business
Results for the year ended 31 December 2025
Cambridge Cognition Holdings plc reported a return to growth in new sales orders, which increased by 73% to £12.8 million in 2025, and an order book up 21% to £16.5 million, though revenue decreased by 10% to approximately £9.4 million due to a weaker opening order book. The company experienced an adjusted EBITDA loss of £0.5 million, an increase from the prior year's loss of £43,000, but successfully raised £1.1 million in gross proceeds through a placing. Borrowings were reduced to £0.9 million, resulting in a net cash position of approximately £0.3 million, and the company anticipates revenue growth in 2026, projecting £9.5 million. Disclaimer*
About this update from Cambridge Cognition Holdings Plc
13 April 2026 Cambridge Cognition Holdings plc ("Cambridge Cognition", the "Company" or the "Group") Results for the year ended 31 December 2025 Return to growth and expanding market opportunities Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces its results for the period ending 31 December 2025. Highlights · New sales orders in year up 73% to £12.8m (2024: £7.4m) · Order book at year end up 21% to £16.5m (2024: £13.6m) · Revenues of c.£9.4m down 10% (2024: £10.3m) · Adjusted EBITDA loss of £0.5m (2024: loss £43k) · Successful placing in August raising gross proceeds of £1.1m · Cash of £1.1m (June 2025: £0.4m, December 2024 £1.3m) · Reduced borrowing to £0.9m (December 2024: £1.9m), resulting in a net cash position of c.£0.3m (December 2024: net debt £0.6m) 2025 saw Cambridge Cognition reverse previous negative trends to deliver new sales order growth and expansion across four market segments that strengthened our position in clinical studies and academic research, while entering professional healthcare and consumer health & wellness markets. Although revenue declined in 2025 due to the weak opening order book, the impact on adjusted EBITDA was limited following previous reductions in the Company's cost base. Encouragingly, we saw positive cashflow from operating activities following a period of previous cash consumption. We believe returning to growth in sales sets the Company up for future revenue, profit and cash generation. This will provide the foundation for strategic investment in our science and technology. At the date of this announcement the Company expects to deliver 2026 revenue of £9.5m, supported by the current Order Book and revenue recognised to date. This is an increase from the £8.8m expected at 31 December 2025. This does not take into account the impact of further new Sales Orders in Q2, Q3 and Q4 2026. Consequently, we expect to see a growth in revenue in the current year. Our objective is to solidify our leadership in serving academic researchers and drug developer...
View stock analysis, news, and events for Cambridge Cognition Holdings Plc